Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Study shows superiority of Chocolate Touch device for opening blocked arteries in the leg

Patients treated for a blocked artery in the leg were significantly more likely to have an open artery without further interventions at 12 months if they received the second-generation paclitaxel-coated balloon catheter known as the Chocolate Touch device compared with those receiving the commercially-available Lutonix drug-coated balloon catheter, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

The findings of a new study suggest that a ketogenic diet -; which is low in carbohydrates and protein, but high in fat -; helps to kill pancreatic cancer cells when combined with a triple-drug therapy developed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

22 Mar 2022

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

12 Feb 2022

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (CAS) recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021

New genetic classifier can predict the sensitivity of neoadjuvant chemotherapy for breast cancer

A research team by Prof. YANG Wulin and DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences recently proposed a genetic classifier that can predict the sensitivity of neoadjuvant chemotherapy for breast cancer in the field of tumor molecular markers.

15 Sep 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

Innovative testing platform could enable more precise, personalized immunotherapy

An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells.

22 Jul 2021

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Oncotarget published "Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells" which reported that to guide studies in cancer patients, relacorilant, an investigational selective GR modulator that antagonizes cortisol activity, was assessed in various tumor types, with multiple cytotoxic combination partners, and in the presence of physiological cortisol concentrations.

28 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices

Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5 million people in the United States. Patients with this circulatory disorder may develop severe leg pain or unhealing wounds that require a minimally invasive revascularization procedure to open the blood vessels to improve blood flow.

18 May 2021

New strategy could increase the effectiveness of chemotherapy treatments

New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors' intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.

7 May 2021

Drug synthesized from Kentucky-grown plant shows promise in treating ovarian cancer

A new study from University of Kentucky Markey Cancer researchers shows that Artemisia annua, a plant that has been traditionally used for its anti-malaria components, shows promise in treating ovarian cancer.

26 Apr 2021

Treatment resistance in triple-negative breast cancers linked to softer tissue environment

Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells.

3 Apr 2021

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.

30 Mar 2021

Study reveals potential risk factors for developing nerve damage after cancer treatment

A low hemoglobin count, older age and high BMI are possible risk factors for developing nerve damage after cancer treatment, a UNSW-led study has found.

4 Mar 2021

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC), and Distal Extrahepatic Tumors (DET).

3 Feb 2021